Trials / Unknown
UnknownNCT04505995
Azacitidine and Homoharringtonine in JMML
Efficacy of Concomitant Use of Azacitidine and Homoharringtonine in Children With Juvenile Myelomonocytic Leukemia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Air Force Military Medical University, China · Academic / Other
- Sex
- All
- Age
- 1 Month – 18 Years
- Healthy volunteers
- Not accepted
Summary
Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine and homoharringtonine | Concommitant use of azacitidine and homoharringtonine |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2023-01-01
- Completion
- 2025-01-01
- First posted
- 2020-08-10
- Last updated
- 2020-08-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04505995. Inclusion in this directory is not an endorsement.